Neurocrine Biosciences (NBIX) News Today $135.42 +0.46 (+0.34%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-three ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, seventeen have issDecember 21 at 3:03 AM | marketbeat.comNeurocrine says Crenessity now available in U.S.December 21 at 1:19 AM | markets.businessinsider.comNeurocrine Announces Commercial Launch Of Crenessity In USDecember 21 at 1:19 AM | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)December 20 at 8:17 PM | markets.businessinsider.comNeurocrine Biosciences Announces U.S. Launch of CRENESSITY for Classic Congenital Adrenal ...December 20 at 12:10 PM | gurufocus.comNeedham & Company LLC Reaffirms "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX)Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research note on Friday.December 20 at 11:22 AM | marketbeat.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,091 Shares of StockDecember 20 at 8:50 AM | insidertrades.comNeurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaDecember 20 at 8:00 AM | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 SharesNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 1,091 shares of the firm's stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now directly owns 2,507 shares of the company's stock, valued at $338,445. This represents a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.December 19 at 7:24 PM | marketbeat.comJ.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)December 19 at 2:04 AM | markets.businessinsider.comFinancial Review: Clarus Therapeutics (OTCMKTS:CRXTQ) and Neurocrine Biosciences (NASDAQ:NBIX)December 19 at 1:49 AM | americanbankingnews.comNeurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And GrowthDecember 18 at 10:27 AM | seekingalpha.comTidal Investments LLC Has $1.73 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tidal Investments LLC raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 52.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,043 shares of the comDecember 18 at 4:53 AM | marketbeat.comHighTower Advisors LLC Has $1.10 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)HighTower Advisors LLC trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,587 shares of the company's stock aDecember 18 at 3:34 AM | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given "Outperform" Rating at WedbushDecember 18 at 3:16 AM | americanbankingnews.comBarclays Keeps Their Buy Rating on Neurocrine (NBIX)December 17, 2024 | markets.businessinsider.comFranklin Resources Inc. Lowers Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Franklin Resources Inc. cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 17.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 664,336 shares of the company's stock after selling 144,114 sharesDecember 17, 2024 | marketbeat.comNeurocrine Biosciences' (NBIX) "Outperform" Rating Reaffirmed at William BlairDecember 17, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Neurocrine Biosciences (NASDAQ:NBIX)December 17, 2024 | americanbankingnews.comPromising Growth Trajectory for Neurocrine’s Crenessity in Treating Congenital Adrenal HyperplasiaDecember 16, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Neurocrine (NBIX)December 16, 2024 | markets.businessinsider.comNeurocrine Biosciences (NASDAQ:NBIX) Shares Up 5% - Should You Buy?Neurocrine Biosciences (NASDAQ:NBIX) Shares Up 5% - Here's What HappenedDecember 16, 2024 | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Neurocrine Biosciences (NASDAQ:NBIX)William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Monday.December 16, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given Outperform Rating at WedbushWedbush restated an "outperform" rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday.December 16, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday.December 16, 2024 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Neurocrine (NBIX)December 16, 2024 | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,859,232 shares ofDecember 16, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLCBarclays PLC lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 181,591 shares of the company's stock after selling 40,798 shares during the quarter. BarcDecember 15, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,944 sharesDecember 15, 2024 | marketbeat.comNeurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal HyperplasiaDecember 14, 2024 | markets.businessinsider.comNeurocrine Biosciences Inc (NBIX) Announces FDA Approval of CRENESSITY for Classic Congenital ...December 13, 2024 | gurufocus.comNeurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaDecember 13, 2024 | prnewswire.comUS FDA approves Neurocrine Biosciences' genetic disorder drugDecember 13, 2024 | reuters.com28,088 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Tri Ri Asset Management CorpTri Ri Asset Management Corp bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 28,088 shares of the company's stock, valued at approximately $3,236,000.December 13, 2024 | marketbeat.com17,230 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Virtu Financial LLCVirtu Financial LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 17,230 shares of the company's stock, valued at apprDecember 13, 2024 | marketbeat.comEP Wealth Advisors LLC Acquires New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)EP Wealth Advisors LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,191 shares of the company's stock, valued at approximately $483,December 13, 2024 | marketbeat.comTri Ri Asset Management Corp Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tri Ri Asset Management Corp acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 28,088 shares of the company's stock, valued at approximately $3,105December 12, 2024 | marketbeat.comVestcor Inc Sells 4,884 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Vestcor Inc decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 19.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,208 shares of the company's stock afDecember 11, 2024 | marketbeat.comXTX Topco Ltd Purchases 5,322 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)XTX Topco Ltd raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 159.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 8,665 shares of the company's stock after acquiring an additional 5,322 shares during the period. XDecember 11, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Wellington Management Group LLPWellington Management Group LLP trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 718,226 shares of the company's sDecember 11, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Fmr LLCFmr LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 28.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,106 shares of the company's stock after selling 95December 10, 2024 | marketbeat.comY Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,781 shares of the company's stock, valued at approxDecember 9, 2024 | marketbeat.comState Street Corp Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)State Street Corp boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,148,293 shares ofDecember 9, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Royal London Asset Management Ltd.Royal London Asset Management Ltd. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,533 shares of theDecember 9, 2024 | marketbeat.comVerition Fund Management LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Verition Fund Management LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,325 shares of the comDecember 9, 2024 | marketbeat.comWorldquant Millennium Advisors LLC Sells 51,003 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Worldquant Millennium Advisors LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 32.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 107,482 shares of theDecember 8, 2024 | marketbeat.comSoros Fund Management LLC Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Soros Fund Management LLC trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 23.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,000 shares ofDecember 6, 2024 | marketbeat.comEdgestream Partners L.P. Sells 38,928 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Edgestream Partners L.P. lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 88.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,266 shares of the company's stock after selling 38,928 sharDecember 6, 2024 | marketbeat.comJanus Henderson Group PLC Sells 179,007 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Janus Henderson Group PLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 792,196 shares of the comDecember 5, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Lifted by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,840 shares of the company's stocDecember 4, 2024 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.670.61▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼3412▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Exelixis News Today Repligen News Today Madrigal Pharmaceuticals News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
